Drug Profile
BAL 19403
Alternative Names: BAL19403Latest Information Update: 06 Jul 2011
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Class Anti-inflammatories; Antiacnes; Macrolides; Skin disorder therapies
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne; Bacterial infections
Most Recent Events
- 01 Oct 2007 Phase-I clinical trials in Acne in Switzerland (Topical)
- 01 Oct 2007 Phase-I clinical trials in Bacterial infections in Switzerland (Topical)
- 01 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the adverse events, pharmacokinetics, and Bacterial Infections pharmacodynamics sections